Ratings
0
Nobody has rated this yet. Be the first!
Works
2
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
